Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells

Lorenz C. Hofbauer, Sundeep Khosla, Colin R. Dunstan, David L. Lacey, Thomas C. Spelsberg, B. Lawrence Riggs

Research output: Contribution to journalArticle

533 Citations (Scopus)

Abstract

The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370% and 320%, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60% and 73%, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.

Original languageEnglish (US)
Pages (from-to)4367-4370
Number of pages4
JournalEndocrinology
Volume140
Issue number9
StatePublished - 1999

Fingerprint

Osteoprotegerin
Estrogens
Estrogen Receptors
Gene Expression
Proteins
Osteoblasts
Bone and Bones
Estradiol
RANK Ligand
Osteopetrosis
Messenger RNA
Estrogen Receptor Modulators
Tumor Necrosis Factor Receptors
Osteogenesis
Knockout Mice
Transgenic Mice
Osteoporosis
Cell Line

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999). Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140(9), 4367-4370.

Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. / Hofbauer, Lorenz C.; Khosla, Sundeep; Dunstan, Colin R.; Lacey, David L.; Spelsberg, Thomas C.; Riggs, B. Lawrence.

In: Endocrinology, Vol. 140, No. 9, 1999, p. 4367-4370.

Research output: Contribution to journalArticle

Hofbauer, LC, Khosla, S, Dunstan, CR, Lacey, DL, Spelsberg, TC & Riggs, BL 1999, 'Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells', Endocrinology, vol. 140, no. 9, pp. 4367-4370.
Hofbauer, Lorenz C. ; Khosla, Sundeep ; Dunstan, Colin R. ; Lacey, David L. ; Spelsberg, Thomas C. ; Riggs, B. Lawrence. / Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. In: Endocrinology. 1999 ; Vol. 140, No. 9. pp. 4367-4370.
@article{4e14412a17eb4940a97a6f4289be5eb5,
title = "Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells",
abstract = "The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370{\%} and 320{\%}, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60{\%} and 73{\%}, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.",
author = "Hofbauer, {Lorenz C.} and Sundeep Khosla and Dunstan, {Colin R.} and Lacey, {David L.} and Spelsberg, {Thomas C.} and Riggs, {B. Lawrence}",
year = "1999",
language = "English (US)",
volume = "140",
pages = "4367--4370",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells

AU - Hofbauer, Lorenz C.

AU - Khosla, Sundeep

AU - Dunstan, Colin R.

AU - Lacey, David L.

AU - Spelsberg, Thomas C.

AU - Riggs, B. Lawrence

PY - 1999

Y1 - 1999

N2 - The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370% and 320%, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60% and 73%, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.

AB - The identity of the paracrine mediator(s) of the antiresorptive action of estrogen on bone cells is controversial. Osteoprotegerin (OPG) was recently identified as a soluble member of the tumor necrosis factor (TNF) receptor (TNF-R) superfamily that is secreted by osteoblast lineage cells and acts by binding to and neutralizing its cognate ligand, OPG-L, a required factor for osteoclastogenesis. OPG prevents bone loss when administered to ovariectomized rats, induces osteoporosis when ablated in knock-out mice, and induces osteopetrosis when overexpressed in transgenic mice. In conditionally immortalized, human osteoblastic hFOB/ER-3 and hFOB/ER-9 cell lines containing physiological concentrations of ~800 and ~8,000 functional estrogen receptors (ER)/nucleus, respectively, we found that 17β-estradiol dose- and time-dependently increased OPG mRNA and protein levels to maximal levels of 370% and 320%, respectively (P < 0.001); co-treatment with the 'pure' antiestrogen ICI 182,780 abrogated these effects completely. 17β-Estradiol also dose-dependently increased OPG mRNA and protein levels in normal human osteoblasts with ~400 ER/nucleus by 60% and 73%, respectively. Thus, estrogen enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of estrogen on bone.

UR - http://www.scopus.com/inward/record.url?scp=0033304632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033304632&partnerID=8YFLogxK

M3 - Article

C2 - 10465311

AN - SCOPUS:0033304632

VL - 140

SP - 4367

EP - 4370

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -